25 Jul

Angiolite BTK, below the knee sirolimus-eluting stent, receives CE Mark Approval

iVascular announces the release of Angiolite BTK, a sirolimus-eluting stent which has received CE Mark Approval for treating chronic and acute arterial lesions in lower limbs below the knee (BTK), improving blood flow in severe claudication and critical limb ischaemia.

Angiolite BTK design has been specifically elaborated for drug eluting stent and benefits from iVascular proprietary coating nanotechnology that yields a multilayer thin coating with optimal kinetics.

“Having the right bail-out options, when performing BTK angioplasty, is extremely important in saving limbs” claims Dr. Peter Goverde (Vascular Surgeon in ZNA Stuivenberg Hospital) “The latest generation DES, like the dedicated Angiolite BTK, can give you a solution and improve the outcome of your treatment.”

The first results of the clinical study led by Dr. Goverde, demonstrated a 6-month primary patency rate of 90% and an amelioration in wound healing and reduction of major amputation.

“With this new launch, iVascular is proud to offer a complete portfolio for the treatment of endovascular pathologies” – said Lluis Duocastella, CEO of iVascular.

Share this